1Vogel C, Cobleigh M, Tripathy D, et al. First-line, nonhormonal treatment of woman with HER2 overexpressing metastatic breast cancer with herceptin(trastuzumab,humanized anti-HER2 antibody) . Proc Am Soc Clin Oncol,2000,19: 71a.
2Bianco AR,De laurentiis M,Carlomagno C,et al. HER2overexpression predicts adjuvant tamoxifen failure for early breast cancer: Complete data at 20 years of the naples GUN randomized trial. Proc Am Soc Clin Oncol,2000,19: 75a .
3Pietras RJ,Poen JC,Gallardo D, et al. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cellsoverexpressing this oncogene. Cancer Res, 1999,59:1347 ～1355.
4Wiles DW, Harris WH,Gillett CE,et al. Effect of c-erbB (2) and estrogn receptor status on survival of woman with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer,1999,84: 354～359.
5Klapper LN, Glathe S, Vaisman N, et al. The erbB-2/ HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA, 1999,96:4995～5000.
6Konecoy G,Pegram MD, Beryt M,et al. Therapeutic advantage of chemotherapy drugs in combination with herceptin against human breast cancer cells with HER-2/neu overexpression. Breast Cancer Res Treat. 1999,57:114.
7Wong WL, Bajamonde A, Nelson B, et al. Baseline serum HER2 levels in the pivotal herceptin breast cancer trials:a comparison of 2 ELISA methods. Proc AM Soc Clin Oncol, 2000,19: 77a.
8Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev, 2001,27(3): 137- 142.
9Jalava PJ,Kuopio T,Kortelainen S, et al. Quantitation of erbB2 positivity for evaluation of high-risk patients. Annals of medicine, 2002,34(7/8): 544-553.
10Isaacs C,Stearns V, Hayes DF. New prognostic factors for breast cancer recurrence . Semin Oncol, 2001,28(1):53-67.
4Tsutsui S, Ohno S, Murakami S, et al. Prognostic significance of the coexpression of p53 protein and c-erbB-2 in breast cancer[J]. The American Journal of Surgery, 2003,185(2) : 165.
5Zhang Liangfeng, Bewick, Mary Lafrenie, et al. EGFR and erbB2 differentially regulate Raf-1 translocation and activation[J]. Laboratory investigation, 2002,82(1) :71.
6Jalava PJ, Kuopio T, Kortelainen S, et al. Quantitation of erbB2 positivity for evaluation of high-risk patients[J]. Annals of medicine, 2002,34(7/8) :544.
